用upadacitinib治疗慢性手湿疹:从临床试验和现实世界经验的见解
相关实验视频
Updated: Sep 16, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.2K
概括
口服上巴西提尼布 (UPA) 提供了快速和持续的缓解慢性手湿疹 (CHE) 在患有亚托皮炎 (AD) 的患者. 这种JAK抑制剂在局部治疗失败时提供了一个有希望的替代品.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性手湿疹 (CHE) 是一种使人虚弱的皮肤疾病,通常与亚托皮炎 (AD) 相关.
- 目前用于CHE的局部疗法可能受到有效性,坚持性和耐受性问题的限制.
- 口服上巴西替尼 (UPA) 是作为一种新型治疗阿兹海默氏症患者耐火性CHE的新疗法.
研究的目的:
- 评估口服乌帕达西提尼 (UPA) 在治疗亚托皮性皮肤炎 (AD) 患者慢性手湿疹 (CHE) 的疗效.
- 评估UPA的有效性作为CHE的替代疗法,该疗法对局部治疗无反应.
主要方法:
- 从主要数据库 (PubMed,SCOPUS,EMBASE) 中对CHE治疗的研究进行了叙述性审查.
- 使用手湿疹严重性指数 (HECSI) 测量CHE严重性的随机对照试验 (RCT) 的分析.
- 包括三个不同的患者病例研究,证明现实世界UPA的有效性.
主要成果:
- 在3期AD试验中,在基线时注意到CHE的高患病率 (超过92%).
- 乌帕达西丁 (UPA) 从第1周开始表现出快速的CHE改善 (P≤0.001与安慰剂相比).
- 在接受UPA治疗的患者中,高达83%的患者在第8周实现了显著的CHE改善 (HECSI-75),持续的好处持续到第16周.
结论:
- 口服的上西提尼布可为慢性手湿疹病变提供快速和持续的缓解.
- 对于那些没有对局部疗法的反应的CHE患者来说,UPA代表了一个有前途的治疗选择.
相关概念视频
Hand hygiene
4.2K
Asepsis is the practice of preventing or breaking the chain of infection. The nurse employs aseptic techniques to prevent the spread of microorganisms and reduce the risk of diseases. Hand hygiene is the cornerstone of aseptic techniques and is classified into medical and surgical asepsis. Medical asepsis includes hand hygiene and the use of gloves. Surgical asepsis, or the sterile technique, refers to practices that render and keep objects and areas free of microorganisms.
Hand washing...
Hand washing...
4.2K
Clinical Applications of Epidermal Stem Cells
2.8K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.8K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
275
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
275
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
208
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
208
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
227
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
227
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
238
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
238

